It is known that the activation of NF-κB is a key pathway for the progression of inflammation and fibrosis in diabetic nephropathy, and inhibiting NF-κB activation can reduce the expressions of proinflammatory cytokines and prevent diabetes from progressing to kidney damage [25]. This evidence concerns the gene NFKB1 and diabetic kidney disease.